Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy

BMC Urology

Volumn 10, Issue , 2010, Pages

  Zubac, Dragomir P ^a   Wentzel Larsen, Tore ^b   Seidal, Tomas ^c   Bostad, Leif ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c HALMSTAD HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOSPONDIN 1; BLOOD CLOTTING FACTOR 8; SERINE PROTEINASE INHIBITOR; TUMOR MARKER;

ANGIOGENESIS; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL RENAL CELL CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR VOLUME; CLINICAL TRIAL; DISEASE COURSE; KAPLAN MEIER METHOD; KIDNEY TUMOR; METABOLISM; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PROPORTIONAL HAZARDS MODEL; VASCULARIZATION;

CARCINOMA, RENAL CELL; DISEASE PROGRESSION; FACTOR VIII; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; NEPHRECTOMY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROPORTIONAL HAZARDS MODELS; SERINE PROTEINASE INHIBITORS; THROMBOSPONDIN 1; TUMOR MARKERS, BIOLOGICAL;

EID: 78649536407     PISSN: 14712490     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-10-20     Document Type: Article

References (18)

1. What is the evidence that tumors are angiogenesis dependent? J Folkman, J Natl Cancer Inst 1990 82 1 4 6 10.1093/jnci/82.1.4 1688381
2. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer. SB Fox M Taylor J Grondahl-Hansen S Kakolyris KC Gatter AL Harris, J Pathol 2001 195 2 236 243 10.1002/path.931 11592104
3. Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. DT Eitzman JC Krauss T Shen J Cui Ginsburg, Blood 1996 87 11 4718 4722 8639841
4. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. GA Soff J Sanderowitz S Gately E Verrusio I Weiss S Brem HC Kwaan, J Clin Invest 1995 96 6 2593 2600 10.1172/JCI118323 8675623
5. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. GA McMahon E Petitclerc S Stefansson E Smith MK Wong RJ Westrick D Ginsburg PC Brooks DA Lawrence, J Biol Chem 2001 276 36 33964 33968 10.1074/jbc.M105980200 11441025
6. Type-1 plasminogen activator inhibitor in human renal cell carcinoma. SN Wagner MJ Atkinson S Thanner M Schmitt O Wilhelm M Rotter H Hofler, J Pathol 1996 179 1 95 99 10.1002/(SICI)1096-9896(199605)179:1<95::AID-PATH534>3.0. CO;2-Z 8691352
7. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? G Deng SA Curriden S Wang S Rosenberg DJ Loskutoff, J Cell Biol 1996 134 6 1563 1571 10.1083/jcb.134.6. 1563 8830783
8. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis. K Ohba Y Miyata S Kanda S Koga T Hayashi H Kanetake, J Urol 2005 174 2 461 465 10.1097/01.ju.0000165150.46006.92 16006865
9. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. R Hofmann A Lehmer M Buresch R Hartung K Ulm, Cancer 1996 78 3 487 492 10.1002/(SICI)1097- 0142(19960801)78:3<487::AID-CNCR16>3.0.CO;2-V 8697395
10. Prognostic value of uPA, PAI-1, and DNA content in adult renal cell carcinoma. D Chautard I Dalifard A Chassevent S Guyetant A Daver B Vielle JY Soret, Urology 2004 63 6 1055 1060 10.1016/j.urology.2004.01.013 15183949
11. Renal cell carcinoma: a clinicopathological follow-up study after radical nephrectomy. DP Zubac L Bostad C Gestblom B Kihl T Seidal T Wentzel-Larsen AM Bakke, Scand J Urol Nephrol 2007 41 3 191 197 10.1080/00365590601016552 17469026
12. AJCC cancer staging manual. FL Greene, New York, NY u.a.: Springer 6 2002
13. Prognostic significance of morphologic parameters in renal cell carcinoma. SA Fuhrman LC Lasky C Limas, Am J Surg Pathol 1982 6 7 655 663 10.1097/00000478-198210000-00007 7180965
14. The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival. DP Zubac L Bostad B Kihl T Seidal T Wentzel-Larsen SA Haukaas, J Urol 2009 182 5 2144 2149 10.1016/j.juro.2009.07.015 19758660
15. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. FE Harrell KL Lee DB Mark, Stat Med 1996 15 4 361 387 10.1002/(SICI)1097-0258(19960229)15: 4<361::AID-SIM168>3.0.CO;2-4 8668867
16. Identification of a novel biomarker signature associated with risk for bone metastasis in patients with renal cell carcinoma. B Paule E Deslandes SP Le Mouel L Bastien MP Podgorniak Y Allory A de la Taille S Menashi F Calvo S Mourah, Int J Biol Markers 2010 25 2 112 115 20544684
17. Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene. M Los S Zeamari JA Foekens MF Gebbink EE Voest, Cancer Res 1999 59 17 4440 4445 10485495
18. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. VA Carroll M Ashcroft, Cancer Res 2006 66 12 6264 6270 10.1158/0008-5472.CAN-05-2519 16778202